Neutrophil and monocyte adhesion molecules in bronchopulmonary dysplasia, and effects of corticosteroids

P Ballabh, M Simm, J Kumari, A N Krauss, A Jain, C Califano, M L Lesser, S Cunningham-Rundles

Aims: To study a longitudinal change in the expression of adhesion molecules CD11b, CD18, and CD62L on neutrophils and monocytes in very low birth weight babies who develop respiratory distress syndrome, to compare these levels between bronchopulmonary dysplasia (BPD) and non-BPD infants, and to assess the effect of corticosteroid treatment on these adhesion molecules.

Methods: Of 40 eligible neonates, 11 neonates were oxygen dependent at 36 weeks (BPD 36 weeks), 16 infants were oxygen dependent at 28 days, but not at 36 weeks (BPD d28), and 13 infants did not develop BPD. Seventeen neonates received a six day course of steroid treatment. Expression of CD11b, CD18, and CD62L was measured on neutrophils and monocytes in arterial blood on days 1, 3, 7, 14, 21, and 28, and before and 2–3 days after initiation of dexamethasone treatment by flow cytometry.

Results: CD18 expression on neutrophils and monocytes and CD62L on neutrophils, measured as mean fluorescent intensity, was significantly decreased in BPD neonates compared to non-BPD neonates on days 1–28. Dexamethasone treatment significantly decreased CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18L expression on monocytes.

Conclusions: Decreased CD18 expression on neutrophils and monocytes, and decreased CD62L expression on neutrophils, measured as mean fluorescent intensity during the first four weeks of life in micropremies may be risk factors and early predictors of BPD. Dexamethasone use was associated with decreased expression of CD11b, CD18, and CD62L.

B ronchopulmonary dysplasia (BPD) or chronic neonatal lung disease is a major complication of premature birth associated with barotrauma and high oxygen concentration that continues to affect the micropremies despite advances in clinical care. There is increasing evidence that inflammation is central to the development of BPD and leads to entry of inflammatory cells into the lung during postnatal ventilation, oxygen administration, and exposure to microbial antigen. Neutrophil release may also accelerate this process. Glucocorticoid therapy, specifically dexamethasone, opposes this process, reducing duration of oxygen dependence and incidence of BPD, but has adverse effects on growth and development. Thus, understanding the basic mechanisms of BPD is critical for early identification of neonatal risk and might also reveal key factors that could help form the basis of a rationale for dexamethasone treatment, and potentially lead to other new treatment strategies.

Neutrophil activation and transcapillary migration secondary to inflammation and independent of clinical sepsis has been implicated in respiratory distress syndrome (RDS) which precedes the development of BPD in this setting. The migration of neutrophils to the alveoli occurs in several variable steps involving transient adherence and rolling, mediated by E-selectin, P-selectin, L-selectin, and intercellular adhesion molecule-1 (ICAM-1), followed by firm adhesion, and then transendothelial migration. Selectin deficient mice show impaired leucocyte recruitment. Increased levels of soluble E-selectin and ICAM-1 were observed in cord blood and serum of premature infants who subsequently developed BPD. CD62L, the leucocyte endothelial cellular adhesion molecule, and human analogue of the murine lymph node homing receptor is expressed on T cells, granulocytes, and monocytes.

Downregulation of CD62L on leucocytes is a possible mechanism of neutrophilia during inflammation. L-selectin is involved in leucocyte accumulation. CD 18, the β2-integrin mediating the firm neutrophil adhesion to the endothelium has emerged as a critical adhesion molecule in inflammation. CD11b expression is increased in neonatal infection. Increased CD11b/CD18 on neutrophils has been observed in tracheobronchial fluid of babies who developed BPD. Dexamethasone treatment appears to downregulate the expression of CD11/CD18 and upregulate CD62L in neutrophils, but decreased CD62L in BPD neonates after initiation of dexamethasone has been reported.

In this investigation, we sought to define differences in CD62L, CD18, or CD11b expression in premature infants with RDS that might be linked to the development of BPD in the absence of clinical infection. Adhesion molecule expression on monocytes was examined as well since these cells are both recruited to inflamed sites and produce proinflammatory cytokines. Finally, we studied the effect of dexamethasone therapy on adhesion molecules during the postnatal period.

**PATIENTS AND METHODS**

**Patients**

The Committee on Human Rights in Research institutional review board at Weill Medical College of Cornell University (W-CUMC), New York approved this study. A written consent was obtained from parents of all participating newborns. We studied a sample of 51 infants admitted to the Neonatal Intensive Care Unit, W-CUMC from April 1999 to June 2000. Patients were essentially enrolled consecutively except for logistical reasons or when the mother did not consent. The infants were preterm with RDS, weighing less...
than 1200 g and less than 30 weeks gestation. Babies were considered to have RDS if they required continuous positive airway pressure (CPAP) for more than one day, mechanical ventilation for more than one day, or supplemental oxygen for more than three days, with chest x-ray changes suggestive of RDS. Our practice is to use mechanical ventilation if the oxygen requirement is more than 40–50% for babies on CPAP of 5 cm water, or if there is a significant respiratory acidosis. All babies placed on ventilator received surfactant. Babies with culture proven sepsis in the first two weeks, major congenital anomalies, or death within a month were excluded. Eleven babies were excluded, seven for early death from respiratory failure, and four for neonatal sepis. All premature infants born following preterm labour received a sepsis work up at birth (including blood culture and complete blood cell count), and received antibiotics for 48 hours pending blood culture results.

**Study design**

Arterial blood samples were collected on eligible infants on postnatal days 1, 3, 7, 14, 21, and 28, and before initiation, 2–3 days after, and 2–4 days after discontinuation of dexamethasone. Seventeen babies received dexamethasone treatment after 2 weeks of age for the purpose of weaning them from ventilator or oxygen support according to status at the discretion of their neonatologists. Participation in the study did not alter medical management of the infant. At this time we used dexamethasone in infants with evolving BPD after 2 weeks of postnatal age if the infant had an FIO\(_2\) requirement of >40% and showed no likelihood of weaning over a two day period. Currently use of dexamethasone is more infrequent, and in much smaller doses and shorter duration (0.125 mg/kg for three days) because of emerging concerns.

Blood samples were collected in sodium heparinised tubes and were studied freshly. Infants were followed until discharge and were classified into three groups:

- **Non-BPD (n = 13):** no oxygen at day 28.
- **BPD d28 (n = 16):** oxygen at day 28 and not at 36 weeks corrected gestational age, with radiographic changes consistent with BPD.
- **BPD 36 weeks (n = 11):** these babies were oxygen dependent at day 28 and also at 36 weeks of corrected gestational age.

Chest x-ray of all neonates at 25–30 days of age, who were oxygen dependent on day 28, was reviewed by an experienced paediatric radiologist for the radiological signs of BPD. The radiologist was blinded to study groups.

**Dexamethasone therapy**

Seventeen patients were treated with dexamethasone for six days after 2 weeks of age. Thirteen neonates were started on corticosteroids during the third or fourth week, and four during the fifth or sixth week of life. The dose of dexamethasone was 0.5 mg/kg/day in two divided doses for two days, tapered to 0.25 mg/kg/day for the next two days, then 0.125 mg/kg/day for the last two days. Blood samples were drawn before (pre-dex), after 2–3 days of initiation (on-dex), and 2–4 days after discontinuation (off-dex) of dexamethasone. CD11b, CD18, and CD62L levels normalised with in 2–3 days of discontinuation of dexamethasone. Based on this observation, values while infants were on steroids and until 72 hours after dexamethasone were excluded from general longitudinal analysis. Pre-dex, on-dex, and off-dex levels of CD11b, CD18, and CD62L on neutrophils and monocytes were compared.

**Evaluation of CD11b, CD18, and CD62L**

Freshly obtained arterial blood was stained to evaluate subpopulations of leucocytes expressing adhesion molecules using FITC and PE labelled monoclonal antibodies against CD11b, CD18, and CD62L (Becton Dickinson) by the standard lyse/wash method. The population gates were confirmed by a CD45FITC/CD14PE (Becton Dickinson) stain (lymphocytes are CD45bright/CD14negative, monocytes are CD45bright/CD14bright, granulocytes are CD45+/CD14dim). Percent positive cells and molecule density of CD11b, CD18, and CD62L were measured using Cell Quest software (Becton Dickinson). Percent positive values were standardised using isotype matched irrelevant murine antibodies (Becton Dickinson). Molecule density was estimated using geometric mean of percent positive cells.

**Analysis and statistics**

Repeated measures analysis of covariance (RM ANCOVA) was used to determine whether a particular outcome variable (CD 11b, CD18, and CD62L on neutrophils and monocytes) varied by group (non-BPD versus BPD patients) and whether a group-by-day interaction existed. The repeated measures analysis was adjusted for the covariates gestational age and birth weight. Adjustment for these “confounding” variables was indicated due to their differences across groups (table 1) and correlations with each of the outcome variables. Infants were analysed as non-BPD, BPD 28 days, BPD 36 weeks, and combined BPD. Since both the groups of infants with BPD had chest radiographs consistent with BPD and all the infants in both the groups were oxygen dependent on day 28, two BPD groups were combined to achieve a bigger sample size and referred to as “combined BPD”. No group-by-day interaction was found for any of the six variables for non-BPD infants compared to BPD 28 days, BPD 36 weeks, and combined BPD infants. In the absence of a group-by-day interaction, no separate analysis was performed for each day since lack of interaction indicates that the group effect was uniform across all days. Analysis of residuals suggested that the normality assumptions required for application of RM ANCOVA were tenable. An RM ANCOVA result was considered significant if p < 0.05. RM ANOVA was used to compare pre-dex, on-dex, and off-dex levels of adhesion markers in the three groups of infants, and also to compare absolute neutrophil and monocyte counts on postnatal days 1, 3, 7, 14, 21, and 28.

**RESULTS**

**Characteristics of the study group**

Table 1 gives the characteristics of 40 infants with RDS that completed the study. Infants in the non-BPD group were significantly larger in weight and older in gestational age compared to infants in either clinically defined group of BPD infants, BPD d28, and BPD 36 weeks. Differences were significant for both groups compared with RDS infants who did not develop BPD (p < 0.001 for all comparisons). Only 15% of the non-BPD infants were treated with dexamethasone during the third or fourth week of life compared with 31% of the BPD d28 infants and 55% of the BPD 36 weeks infants. The two infants in the non-BPD group of 27 weeks gestational age were treated with dexamethasone for high ventilator settings and oxygen requirements on postnatal day 15–16. Both responded very well and were off oxygen before postnatal day 28. Infection rates were different in the two groups of BPD infants. To reduce or eliminate effects that dexamethasone treatment might have on adhesion molecule expression, data at all time points during which the infants were on dexamethasone treatment and for three days after discontinuation of dexamethasone were excluded from analysis of longitudinal effects. Similarly, all the data points...
Table 1 Characteristics of infants

<table>
<thead>
<tr>
<th></th>
<th>Non-BPD (n = 13)</th>
<th>BPD d28 (n = 16)</th>
<th>BPD 36 weeks (n = 11)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>White (%)</td>
<td>30.8</td>
<td>43.8</td>
<td>54.5</td>
</tr>
<tr>
<td>Black (%)</td>
<td>46.2</td>
<td>50.0</td>
<td>36.4</td>
</tr>
<tr>
<td>Asian (%)</td>
<td>23.1</td>
<td>6.3</td>
<td>9.1</td>
</tr>
<tr>
<td>Male (%)</td>
<td>46.2</td>
<td>56.3</td>
<td>45.5</td>
</tr>
<tr>
<td>Weight (g)*</td>
<td>1110.9 (134.6)</td>
<td>833.8 (118.6)</td>
<td>670.9 (64.3)</td>
</tr>
<tr>
<td>Gestation (weeks)*</td>
<td>28.8 (1.2)</td>
<td>26.0 (1.1)</td>
<td>24.9 (1.2)</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-dex (n = 26)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postnatal steroid (%)</td>
<td>7 (1.3)</td>
<td>6 (1.8)</td>
<td>5 (1.7)*</td>
</tr>
<tr>
<td>Age group</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>On-dex (n = 26)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postnatal steroid (%)</td>
<td>8 (0.8)</td>
<td>7 (1.4)</td>
<td>7 (0.7)*</td>
</tr>
<tr>
<td>Blood culture positive (%)</td>
<td>0</td>
<td>25.0</td>
<td>45.5</td>
</tr>
<tr>
<td>Blood culture positive (%)</td>
<td>0</td>
<td>25.0</td>
<td>45.5</td>
</tr>
</tbody>
</table>

*Values are mean (SD).

p values for non-BPD versus BPD d28 and BPD 36 weeks for variables including birth weight, gestational age, number of ventilation days, number of days on oxygen, length of NICU stay, postnatal dexamethasone and blood culture positive are < 0.01 each.

<table>
<thead>
<tr>
<th>Absolute neutrophil and monocyte counts</th>
</tr>
</thead>
<tbody>
<tr>
<td>In non-BPD infants, absolute neutrophil count (ANC) remained in the range 2820 (1006) to 5213 (3089) per mm$^3$ (mean (SD)) over the first four weeks of life. However, in the BPD d28 and BPD 36 weeks infants, ANC increased with postnatal age, peaking on day 14 and decreasing thereafter. Similarly, absolute monocyte counts (AMC) were within the range 1666 (626) to 1901 (1694) per mm$^3$ (mean (SD)) in the non-BPD group, increasing postnatally in the BPD d28 and BPD 36 weeks infants, peaking on day 14 and decreasing thereafter. The differences in ANC and AMC between non-BPD and the two BPD groups of infants were significant (RMANOVA, p &lt; 0.01; see fig 4).</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effect of dexamethasone treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>We then assessed the effect of dexamethasone treatment on adhesion molecule expression. Figure 5 shows mean fluorescence for CD11b, CD18, and CD62L on neutrophils and monocytes, before (pre-dex), after 48–72 hours of initiation (on-dex), and after discontinuing steroid (off-dex). Dexamethasone treatment significantly decreased CD11b, CD18, and CD62L expression on neutrophils (p &lt; 0.001, p &lt; 0.0003, and p &lt; 0.0033, respectively; RMANOVA), and CD11b and CD18 expression, but not CD62L on monocytes (p &lt; 0.0008 and p &lt; 0.013 respectively; RMANOVA). Moreover, pairwise comparison between pre-dex and on-dex levels as well as on-dex and off-dex levels for neutrophils CD11b, CD18, and CD62L was done using RMANOVA with postnatal age as a covariate.</td>
</tr>
</tbody>
</table>
CD18, CD62L, and monocytes CD11b, CD18 were significant (p < 0.05, Mann-Whitney U test). All of these values normalised after completion of dexamethasone treatment. There were no significant differences between pre- and off-dexamethasone values.

DISCUSSION

Previous studies have suggested that changes in soluble adhesion molecules in serum and tracheal aspirates may characterise the infant with RDS who develops BPD. This is the first longitudinal study to examine change in the expression of adhesion molecules on circulating neutrophils and monocytes in the premature neonates with RDS who developed BPD compared with those who did not. Our premise was that changes in the expression of CD11b/CD18 and CD62L on circulating neutrophils and monocytes would reflect and perhaps predict the development of BPD in neonates with RDS, independent of sepsis.

The definition of BPD continues to be controversial. BPD has been defined as supplemental oxygen beyond 28 days with radiological abnormalities and also as oxygen dependency at 36 weeks corrected gestational age. Therefore we evaluated changes in adhesion molecule expression in infants with RDS grouped clinically according to postnatal oxygen dependency with radiographic confirmation. Although there were several confounding variables between the non-BPD and BPD groups of infants, we chose to adjust only for two major variables, gestational age and birth weight, but not for Apgar score, length of hospital stay, or other characteristics. BPD is almost exclusively seen in preterm infants of less than 1200 g, and has not been related directly with low Apgar score, length of hospital stay, or duration of ventilation in the absence of prematurity.
Before and after adjustment for birth weight and gestational age, we observed decreased CD18 expression on neutrophils and monocytes, and decreased CD62L expression on neutrophils during the first four weeks of postnatal life in infants who developed BPD. Dexamethasone use was associated with even greater decreased expression of CD11b, CD18, and CD62L.

CD18 on monocytes


table 2 Adjusted mean fluorescence intensities for CD18, CD11b, and CD62L on neutrophils and monocytes in non-BPD and combined BPD infants (BPD) (adjustment made for birth weight and gestational age)

<table>
<thead>
<tr>
<th>Groups</th>
<th>Postnatal days</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
</tr>
<tr>
<td>CD18 on neutrophils</td>
<td>Non-BPD: 361 (51)</td>
</tr>
<tr>
<td></td>
<td>BPD: 239 (37)</td>
</tr>
<tr>
<td>CD18 on monocytes</td>
<td>Non-BPD: 364 (57)</td>
</tr>
<tr>
<td></td>
<td>BPD: 313 (36)</td>
</tr>
<tr>
<td>CD62L on neutrophils</td>
<td>Non-BPD: 264 (104)</td>
</tr>
<tr>
<td></td>
<td>BPD: 1375 (207)</td>
</tr>
</tbody>
</table>

CD18 and CD62L

antibodies against CD62L, and firm adherence is mediated by CD18. CD11b/CD18 have emerged as a critical molecule in neutrophil dependent inflammation. Previous studies have suggested that infants who develop BPD show signs of fetal inflammatory response detectable as IL-6 in cord blood and as an increase in expression of CD11b on neutrophils compared with healthy preterm infants. The pulmonary increase in neutrophils occurs transiently in RDS and becomes persistent in BPD. Markers of inflammation such as ICAM-1 and IL-8 are increased in bronchial lavage fluid in infants who subsequently develop BPD, and correlation with pulmonary neutrophilia has been reported. An increase in inflammatory cytokines, IL-1β, IL-6, and IL-8 precedes the influx of neutrophils found in tracheal aspirates in infants who develop BPD. In addition, increases in soluble E-selectin and ICAM-1 in serum, and L-selectin in tracheal aspirates appear to be associated with the development of BPD. In one study, CD11b/CD18 expression on neutrophils in bronchoalveolar lavage fluid increased over the first 17 days of life in BPD infants. Thus, inflammation is important to the aetiology of BPD. Both IL-6 and CD18/CD11b expression are increased in sepsis in the premature infant. Neonatal neutrophil deficiencies are considered a key factor in neonatal susceptibility to bacterial infection and to affect diapedesis. CD11b/CD18 expression on neonatal neutrophils has been reported as similar to or even increased compared with adults and is not affected by gestational age. This controversy has been resolved by Reddy and colleagues, who observed that neonatal cord blood was comprised of a mixed population of immature neutrophils with reduced β2 integrin expression and mature neutrophils with normal adult levels. Immaturity was associated with younger gestational age and reduced respiratory burst function. The finding that CD18 was decreased in BPD infants, whereas CD11b was not significantly decreased in BPD...
infants compared to non-BPD infants is intriguing. This difference may be related to the fact that expression of CD11b on neutrophils did not increase after day 3 in the non-BPD infants, whereas this trend was observed for CD18 (fig 1). CD11b is very densely expressed on neutrophils, and forms a heterodimer with CD18, but these are separate chains.

Absolute neutrophil counts were significantly higher in BPD infants compared to non-BPD infants consistent with the previous observations in the first five days of life. However, there was no simple relationship between the increasing ANC and AMC in BPD infants over the course of study and decreased surface adhesion molecules (CD18 and CD62L), which might reflect alteration in haematopoiesis or production of immature cells.

We measured serial levels of CD11b, CD18, and CD62L expression on neutrophils and monocytes in blood between BPD and non-BPD infants to look for the critical relationships. In related studies, we found that low soluble L-selectin was associated with the development of BPD. Here we report that CD18 expression on neutrophils and monocytes is significantly decreased in BPD neonates compared to non-BPD neonates on day 1 to day 28. This is the first report of reduced expression of CD18 in association with the development of BPD. Low CD18 may reflect the development of BPD in the infant with RDS for at least two reasons. First this may reflect greater shedding of these molecules in response to inflammation or to stress. Recent studies suggest that stress may reduce CD18 expression and that the circulating neutrophil is not the same as the neutrophil responding to inflammation. Oxidative stress is characteristic in premature infants and is worsened by reduced antioxidant capacity. We speculate that reduced CD18 and CD62L expression may reflect this and that neutrophils with reduced CD18 expression would be preferentially retained in circulating blood, while neutrophils with normal or increased

Figure 4 (A) Absolute neutrophil count in non-BPD, BPD d28, and BPD 36 weeks infants. Data are mean (SD). In non-BPD infants, absolute neutrophil count (ANC) did not change with postnatal age significantly over the first four weeks of life. However, in the two BPD groups of infants, ANC increased with postnatal age, peaking on day 14 and then decreased thereafter. The ANC was significantly increased in BPD d28 and BPD 36 weeks infants compared to non-BPD infants (RMANOVA, p<0.01 each). (B) Absolute monocyte count in non-BPD, BPD d28, and BPD 36 weeks infants. Data are mean (SD). In non-BPD infants, absolute monocyte count (AMC) did not change significantly over the first four weeks of life. However, in the two BPD groups of infants, AMC increased with postnatal age, peaking on day 14 and then decreased thereafter. The AMC was significantly increased in BPD d28 and BPD 36 weeks infants compared to non-BPD infants (RMANOVA, p<0.01 each).

Figure 5 (A) Effect of corticosteroid treatment expression of CD11b, CD18, and CD62L on neutrophils. Data are mean (SD). Expression of CD11b, CD18, and CD62L on neutrophils decreased after initiation of steroid (p<0.001 for all three, RMANOVA). Y-axis (left) represents axis for CD18 and CD62L and Y-1 axis (right) represents axis for CD11b on neutrophils. (B) Effect of corticosteroid treatment expression of CD11b, CD18, and CD62L on monocytes. Data are mean (SD). Expression of CD11b and CD18 on monocytes decreased (p<0.001 and p<0.05 respectively, RMANOVA). The effect was not significant for CD62L on monocytes. Y-axis (left) represents axis for CD18 and CD62L and Y-1 axis (right) represents axis for CD11b on monocytes.
expression might be more likely both to migrate and to be retained in the bronchi and lungs. This interpretation is indirectly supported by the studies of Kotecha et al., who found increased expression of CD11b/CD18 in lavage fluid over the first 17 days of life in infants who developed BPD. Nevertheless, these findings may reflect the existence of a mixed population of mature and immature neutrophils in premature infants as reported by Reddy and colleagues,44 which should be correspondingly greater in infants of younger gestational age. Here correction for birth weight and gestational age did not eliminate the differences between non-BPD and BPD, and so this is modulated by factors other than these.

In the present study, reduction of adhesion molecules during steroid treatment was seen in both non-BPD and BPD babies. The decrease in CD62L after starting dexamethasone has been reported previously in BPD neonates and healthy adults.28 The reduction in mean fluorescence of CD18 after dexamethasone has been shown in cows, but not previously in humans.35 We observed that the expression of CD18 on neutrophils and monocytes, and CD62L on neutrophils, was decreased in BPD infants and that dexamethasone treatment further decreased these levels. Thus dexamethasone is likely to reduce leucocyte count and extravasation, which happens when CD11b/CD18 expression is impaired experimentally. Conversely, administration of recombinant human granulocyte triggering factor in neonatal sepsis causes increased expression of $\beta_2$ integrin in addition to increasing neutrophil number.45 Recent studies suggest that an important function of $\beta_2$ integrin adhesion is induction of intracellular signal transduction in adherent cells, leading to neutrophil cytokine production.46 

This signal transduction pathway involves CD11b/CD18 recruitment of a Toll-I receptor family cascade to modulate NF-κB. Reduced expression of CD18/CD11b/CD18 during dexamethasone treatment should dampen this response. The implications of reduced CD11b/CD18 expression on the inflammatory process in BPD appear to be significant and warrant further investigation.

Authors’ affiliations
P Ballabh, A N Krauss, A Jain, Division of Neonatology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, USA
M Simm, C Califano, S Cunningham-Rundles, Division of Hematology/Oncology/Immunology, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, USA
M L Lesser, Biostatistics Unit North Shore and LI Research Institute, New York, USA

Presented at meeting of the Society of Pediatric Research 2001, Baltimore, on 29 April 2001
Supported by NIH RR06020

REFERENCES
CORRECTION

Please note that there is an error in the author list for the article by Burgess et al (Consent for clinical research in the neonatal intensive care unit: a retrospective survey and a prospective study Arch Dis Child Fetal Neonatal Ed 2003;88:F280–F286) shown on the FNN July online table of contents (www.archdischild.com). The correct list is shown here:
AC Fenton is the author of the commentary which accompanies this article. The error is much regretted.